Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Termination of osteoporosis drug odanacatib due to stroke risk means a loss for Merck in reliving the glory days of branded Fosamax.
You may also be interested in...
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
The latest drug development news and highlights from our FDA Performance Tracker.
Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?
Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.
Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck
Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.